VISTAGEN THERAPEUTICS, INC. Debt Conversion, Converted Instrument, Amount
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Debt Conversion, Converted Instrument, Amount of $0 for the 12-month period ending 2017-03-31, per its 10-K filed 2017-06-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2017-06-29
- VISTAGEN THERAPEUTICS, INC. debt conversion, converted instrument, amount for the quarter ending 2016-03-31 was $1.69M.
- VISTAGEN THERAPEUTICS, INC. debt conversion, converted instrument, amount for the quarter ending 2015-12-31 was $0.00.
- VISTAGEN THERAPEUTICS, INC. debt conversion, converted instrument, amount for the quarter ending 2015-09-30 was $1.80M.
- VISTAGEN THERAPEUTICS, INC. debt conversion, converted instrument, amount for the quarter ending 2015-06-30 was $15.40M.
- VISTAGEN THERAPEUTICS, INC. debt conversion, converted instrument, amount for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- VISTAGEN THERAPEUTICS, INC. debt conversion, converted instrument, amount for fiscal 2016 was $18.89M.
- VISTAGEN THERAPEUTICS, INC. debt conversion, converted instrument, amount for fiscal 2013 was $1.56M.
| Period end | Debt Conversion, Converted Instrument, Amount 1 month | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month | Debt Conversion, Converted Instrument, Amount 184 month |
|---|---|---|---|---|---|---|
| 2017-03-31 | $0.00 10-K · filed 2017-06-29 | |||||
| 2016-03-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2017-06-29 | $1.69M derived: sum of 2 quarters · filed 2017-06-29 | $3.49M derived: sum of 3 quarters · filed 2017-06-29 | $18.89M 10-K · filed 2017-06-29 | ||
| 2015-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-02-16 | $1.80M derived: sum of 2 quarters · filed 2016-02-16 | $17.20M 10-Q · filed 2016-02-16 | |||
| 2015-11-13 | $542.00 10-Q · filed 2015-11-16 | |||||
| 2015-09-30 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-11-16 | $17.20M 10-Q · filed 2015-11-16 | ||||
| 2015-06-30 | $15.40M 10-Q · filed 2015-08-14 | |||||
| 2014-03-31 | $4.37M 10-K · filed 2014-06-25 | |||||
| 2013-03-31 | $1.56M 10-K · filed 2014-06-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |